EUVIMEDEUVIMED entdecken
Kohortenstudie

Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients

William Cranwell iD, Nekma Meah, Dmitri Wall, Bevin Bhoyrul, Bokhari Laita, Rodney D Sinclair iD

Australasian Journal of Dermatology · 2024

DOI: 10.1111/ajd.14325 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von William Cranwell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sinclair Dermatology, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Alopecia Areata. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is an autoimmune hair loss disorder characterised by collapse of hair follicle immune privilege and mediated by autoreactive CD8+ T lymphocytes and natural killer cells. Treatment is often unsatisfactory. The Janus kinase‐signal transducer and activator of transcription (JAK–STAT) pathway is implicated in the pathogenesis of AA and Janus Kinase inhibitor (JAKi) medications are promising emerging treatments for AA.

Objectives

We evaluated the safety and effectiveness of tofacitinib in a real‐world setting over 18 months of treatment.

Methods

A retrospective cohort study of all patients with scalp AA commenced on tofacitinib between 1 November 2016 and 31 May 2019. The primary endpoint was the percent change in Severity of Alopecia Tool (SALT) score at 18 months.

Results

Two hundred and two patients were included. After 18 months of treatment, 55.9%, 42.6% and 29.2% achieved 50%, 75% and 90% reductions in their SALT scores respectively. Increased duration of AA was a negative predictor of hair regrowth. Males and patients with baseline SALT ≥90 were slower to respond to treatment in the first 12 months. One hundred and twenty‐four patients and 168 patients received concomitant systemic corticosteroids or low‐dose oral minoxidil during tofacitinib therapy respectively. There were no serious adverse events.

Conclusion

Tofacitinib was a safe and effective treatment for patients with moderate‐to‐severe AA. Further randomised controlled studies are needed to establish the optimal treatment regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesPiperidinesAlopecia AreataHumansMaleRetrospective StudiesFemaleAdultMiddle AgedYoung AdultMinoxidilTreatment OutcomeProtein Kinase InhibitorsSeverity of Illness IndexAdrenal Cortex HormonesAdolescentJanus Kinase InhibitorsCohort StudiesSex Factors

Stichwörter der Autor:innen

Janus kinasealopecia areataminoxidiltofacitinib

Substanzen

tofacitinibPyrimidinesPiperidinesMinoxidilProtein Kinase InhibitorsAdrenal Cortex HormonesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Sinclair Dermatology, Melbourne, Victoria, Australia.
  • St Helens & Knowsley NHS Trust, Prescot, UK.
  • Faculty of Biology, Medicine and Health, Manchester University, Manchester, UK.
  • National and International Skin Registry Solutions (NISR), Dublin, Ireland.
  • Hair Restoration Blackrock, Dublin, Ireland.
  • Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin, Ireland.

ORCID-Profile: William Cranwell, Rodney D Sinclair

Zitieren

APA

Cranwell, W., Meah, N., Wall, D., Bhoyrul, B., Laita, B., & Sinclair, R. D. (2024). Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14325

Vancouver

Cranwell W, Meah N, Wall D, Bhoyrul B, Laita B, Sinclair RD. Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14325

BibTeX
@article{Cranwell2024,
  author = {Cranwell, William and Meah, Nekma and Wall, Dmitri and Bhoyrul, Bevin and Laita, Bokhari and Sinclair, Rodney D},
  title = {Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients},
  journal = {Australasian Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ajd.14325}
}
Kostenlos starten →